ArticleAnnals of medicine and surgery (2012)2023

Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa.

Afsheen Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.